LianBio (the ?company?) announced that the company has entered into an agreement with Janssen Pharmaceutica NV (?Janssen?), whereby Lian has assigned to Janssen, LianBio?s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radioenhancer, in China, South Korea, Singapore and Thailand. Under the terms of the agreement, LianBio will receive a one-time payment of $25 million. In addition, LianBio is eligible to receive a sales milestone payment of $5 million.

Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer than six months. In July 2023, Nanobiotix granted Janssen a worldwide exclusive license, excepting territories previously licensed to LianBio, for the co-development and commercialization of NBTXR3.